Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.33 CAD
Change Today -0.005 / -1.52%
Volume 207.7K
ASP On Other Exchanges
As of 3:09 PM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

acerus pharmaceuticals corp (ASP) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/20/15 - C$0.86
52 Week Low
10/1/15 - C$0.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

acerus pharmaceuticals corp (ASP) Related Businessweek News

No Related Businessweek News Found

acerus pharmaceuticals corp (ASP) Details

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, develops, distributes, and sells medications for male hypogonadism, female sexual dysfunction, and respiratory disorders. It holds a license for the development and marketing rights to various products utilizing a bioadhesive intranasal gel drug delivery technology platform; and owns a novel unit-dose dry powder inhaler/nasal dispersion system. The company’s approved products include Natesto, a bioadhesive intranasal gel formulation of testosterone; and Estrac (17-beta estradiol), which provides symptomatic relief of menopausal symptoms. It is also developing Tefina, an intranasal, low-dose gel formulation of testosterone for women experiencing female orgasmic disorder. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation is headquartered in Mississauga, Canada.

19 Employees
Last Reported Date: 03/5/15

acerus pharmaceuticals corp (ASP) Top Compensated Officers

Chief Executive Officer, President, Non Indep...
Total Annual Compensation: $339.5K
President of Trimel BioPharma SRL
Total Annual Compensation: $215.2K
Vice President of Legal Affairs, Corporate Se...
Total Annual Compensation: $182.2K
Vice President of Scientific Affairs
Total Annual Compensation: $208.2K
Compensation as of Fiscal Year 2014.

acerus pharmaceuticals corp (ASP) Key Developments

Trimel Pharmaceuticals Corp. has Changed its Name to Acerus Pharmaceuticals Corporation

Trimel Pharmaceuticals Corp. changed its name to Acerus Pharmaceuticals Corporation.

Trimel Pharmaceuticals Corporation Commends FDA Approval of the First Treatment for Female Sexual Dysfunction

Trimel Pharmaceuticals Corporation communicated its support of the U.S. Food and Drug Administration’s (FDA) decision to approve ADDYI (flibanserin; developed by Sprout Pharmaceuticals), the first treatment option for female sexual dysfunction (FSD). Trimel is currently developing TEFINA, a ‘use as required’, low-dose nasal testosterone gel treatment for female orgasmic disorder, a subset of FSD. Female orgasmic disorder (FOD) is characterized by a persistent difficulty experiencing orgasm and/or markedly reduced intensity of orgasmic sensations. In a survey of over 1,700 women aged 18 to 59, 43% acknowledged some form of sexual dysfunction. The data suggests that 32% of the women lacked interest in sex and 26% could not experience orgasm. Currently, there are no approved treatments for FOD.

Trimel Pharmaceuticals Corp. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Trimel Pharmaceuticals Corp. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenues of $2.7 million against nil for second quarter 2014. LBITDA was $0.9 million against $6.8 million for second quarter 2014. Adjusted LBITDA was $0.4 million against $4.9 million for second quarter 2014. Loss before income taxes was $1,627,000 compared to $7,460,000 a year ago. Net loss was $1,627,000 compared to $7,460,000 a year ago. Basic and diluted net loss per common share was $0.01 compared to $0.05 a year ago. For the six months, the company reported revenue of $5,955,000. Loss before income taxes was $1,755,000 compared to $10,038,000 a year ago. Net loss was $1,665,000 compared to $10,038,000 a year ago. Basic and diluted net loss per common share was $0.01 compared to $0.06 a year ago. Cash flows used in operating activities of $1,673,000 compared to $13,374,000 a year ago. Acquisition of property and equipment, net of deposits was $224,000 compared to $59,000 a year ago. Adjusted LBITDA was $604,000 compared to $8,131,000 a year ago. EBITDA was $17,000 compared to LBITDA of $8,477,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ASP:CN C$0.33 CAD -0.005

ASP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ASP.
View Industry Companies

Industry Analysis


Industry Average

Valuation ASP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.0x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACERUS PHARMACEUTICALS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at